ATE308992T1 - Attenuierte bakterien verwendbar als impstoffe - Google Patents

Attenuierte bakterien verwendbar als impstoffe

Info

Publication number
ATE308992T1
ATE308992T1 AT02755363T AT02755363T ATE308992T1 AT E308992 T1 ATE308992 T1 AT E308992T1 AT 02755363 T AT02755363 T AT 02755363T AT 02755363 T AT02755363 T AT 02755363T AT E308992 T1 ATE308992 T1 AT E308992T1
Authority
AT
Austria
Prior art keywords
vaccines
attenuated
bacteria
enterotoxins
attenuate
Prior art date
Application number
AT02755363T
Other languages
English (en)
Inventor
Arthur Turner
Judith Greenwood
Jonathan Stephens
Juliet Beavis
Michael Darsley
Original Assignee
Acambis Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9921935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE308992(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acambis Res Ltd filed Critical Acambis Res Ltd
Application granted granted Critical
Publication of ATE308992T1 publication Critical patent/ATE308992T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT02755363T 2001-09-11 2002-09-11 Attenuierte bakterien verwendbar als impstoffe ATE308992T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0121998.9A GB0121998D0 (en) 2001-09-11 2001-09-11 Attenuated bacteria useful in vaccines
PCT/GB2002/004164 WO2003022307A1 (en) 2001-09-11 2002-09-11 Attenuated bacteria useful in vaccines

Publications (1)

Publication Number Publication Date
ATE308992T1 true ATE308992T1 (de) 2005-11-15

Family

ID=9921935

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02755355T ATE308991T1 (de) 2001-09-11 2002-09-11 Bakterieller impfstoff
AT02755363T ATE308992T1 (de) 2001-09-11 2002-09-11 Attenuierte bakterien verwendbar als impstoffe

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT02755355T ATE308991T1 (de) 2001-09-11 2002-09-11 Bakterieller impfstoff

Country Status (10)

Country Link
US (4) US7951361B2 (de)
EP (2) EP1425037B1 (de)
AT (2) ATE308991T1 (de)
AU (2) AU2002321652B2 (de)
CA (2) CA2459586A1 (de)
DE (2) DE60207277T2 (de)
DK (2) DK1425037T3 (de)
ES (2) ES2256515T5 (de)
GB (1) GB0121998D0 (de)
WO (2) WO2003022306A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0121998D0 (en) 2001-09-11 2001-10-31 Acambis Res Ltd Attenuated bacteria useful in vaccines
WO2005017128A2 (en) * 2003-02-26 2005-02-24 University Of Massachusetts Improved reagents for recombinogenic engineering and uses thereof
GB0325494D0 (en) * 2003-10-31 2003-12-03 Sbl Vaccin Ab Expression system
EP1543836A1 (de) * 2003-12-17 2005-06-22 Berna Biotech AG Rekombinante Stamm von Vibrio cholerae und Impfstoff, der diesem Stamm enthält
WO2005113827A2 (en) * 2004-05-19 2005-12-01 THE UNITED STATES OF AMERICA AS REPRESENTED BY THESECRETARY OF THE ARMY, Walter REED ARMY INSTITUTE OF RESEARCH Construction of live attenuated shigella vaccine strains that express cfa/i antigens (cfab and cfae) and the b subunit of heat-labile enterotoxin (ltb) from enterotoxigenic e. coli
EP1855718B1 (de) * 2005-01-11 2016-10-12 The United States of America as represented by The Secretary of The Navy Donor Strang komplementierte Adhesine als immunogen gegen Escherichia coli.
FR2890859B1 (fr) 2005-09-21 2012-12-21 Oreal Oligonucleotide d'arn double brin inhibant l'expression de la tyrosinase
WO2007117339A2 (en) * 2006-01-11 2007-10-18 The United States Of America As Respresented By The Secretary Of The Navy Adhesin-enterotoxin chimera based immunogenic composition against entertoxigenic escherichia coli
CN101378780A (zh) * 2006-02-01 2009-03-04 Sbl疫苗公司 重组细菌中的肠产毒性大肠杆菌定居因子(cf)抗原
WO2009004002A1 (en) * 2007-07-02 2009-01-08 Sbl Vaccin Ab Hybrid operon for expression of colonization factor (cf) antigens of enterotoxigenic escherichia coli
US9410157B2 (en) 2010-07-30 2016-08-09 Wisconsin Alumni Research Foundation Systems and methods for the secretion of recombinant proteins in gram negative bacteria
KR101940357B1 (ko) * 2011-09-12 2019-01-18 스칸디나비안 바이오파마 홀딩 에이비 세포 표면 상 ｅｔｅｃ ｃｓ６ 항원 제시의 증가 방법 및 그것의 수득가능한 산물들
EP2897638A1 (de) 2012-09-24 2015-07-29 Montana State University-Bozeman Rekombinanter lactococcus lactis zur expression des escherichia coli-kolonisationsfaktor-antigens i (cfa/i) fimbriae und verfahren zu deren verwendung
AU2013345316B2 (en) 2012-11-19 2016-04-14 The United States Of America As Represented By The Secretary Of The Navy Recombinant polypeptide construct comprising multiple enterotoxigenic Escherichia coli fimbrial subunits
US10500261B2 (en) 2014-11-05 2019-12-10 The United States Of America As Represented By The Secretary Of The Navy Synthetic antigen constructs against campylobacter jejuni
US9925254B2 (en) 2014-11-05 2018-03-27 The United States Of America As Represented By The Secretary Of The Navy Synthetic antigen constructs against Campylobacter jejuni
CN105063073A (zh) * 2015-09-16 2015-11-18 中国科学院南海海洋研究所 一种弧菌通用的基因敲除自杀载体及其应用
CA3095914A1 (en) * 2018-04-03 2019-10-10 University Of Maryland, Baltimore Enhanced shigella-enterotoxigenic e. coli multi-valent vaccine

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58146596A (ja) * 1982-02-25 1983-09-01 Takeda Chem Ind Ltd 組換えｄｎａ、それで形質転換させた微生物およびそれらの用途
US4935364A (en) * 1983-03-04 1990-06-19 Swiss Serum And Vaccine Institute Berne Method of isolating restriction fragment deletions in vibrio cholerae and products thereof
GB8730037D0 (en) 1987-12-23 1988-02-03 Wellcome Found Vaccines
GB8912330D0 (en) 1989-05-30 1989-07-12 Wellcome Found Live vaccines
GB9007194D0 (en) 1990-03-30 1990-05-30 Wellcome Found Live vaccines
SE9100556D0 (sv) * 1991-02-26 1991-02-26 Holmgren Jan Preparation and use of formalin-killed colonization-factor-antigen (cfa)-expressing e coli organisms for vaccination against enteric infection/diarrhea caused by enterotoxigenic e coli bacteria in humans
JP3415145B2 (ja) 1991-03-05 2003-06-09 ザ ウエルカム ファウンデーション リミテッド 弱毒化細菌における組換えタンパク質の発現
US7118758B1 (en) * 1997-01-24 2006-10-10 The United States Of America As Represented By The Secretary Of The Army Transformed bacteria producing CS6 antigens as vaccines
US6019982A (en) * 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
US6682729B1 (en) * 1995-05-03 2004-01-27 University Of Maryland, Baltimore Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same
US7404961B2 (en) * 1996-08-02 2008-07-29 The United States Of America As Represented By The Secretary Of The Army Peptides responsive to antibodies against consensus peptide of the CS4-CFA/I family proteins
GB9806449D0 (en) * 1998-03-25 1998-05-27 Peptide Therapeutics Ltd Attenuated bacteria useful in vaccines
SE9801852D0 (sv) 1998-05-26 1998-05-26 Sbl Vaccin Ab Method of producing thy A-strains of Vibro cholerae, suck strains and their use
SE515285C2 (sv) 1998-12-18 2001-07-09 Sbl Vaccin Ab Oralt vaccin mot diarré
EP1216303A1 (de) * 1999-09-15 2002-06-26 Mogam Biotechnology Research Institute Detoxifizierte mutanten des hitze-labilen enterotoxins aus escherichia coli
HUP0300297A3 (en) * 2000-04-20 2005-09-28 Univ Maryland Baltimore Baltim Isolation and characterization of the csa operon (etec-cs4 pili) and methods of using same
GB0121998D0 (en) 2001-09-11 2001-10-31 Acambis Res Ltd Attenuated bacteria useful in vaccines
WO2007117339A2 (en) * 2006-01-11 2007-10-18 The United States Of America As Respresented By The Secretary Of The Navy Adhesin-enterotoxin chimera based immunogenic composition against entertoxigenic escherichia coli
WO2010048322A1 (en) * 2008-10-21 2010-04-29 Emergent Product Development United Kingdom Use of e. coli surface antigen 3 sequences for the export of heterologous antigens
WO2011002836A2 (en) * 2009-06-30 2011-01-06 Stc.Unm Attenuated enterohemorrhagic e.coli-based vaccine vector and methods relating thereto

Also Published As

Publication number Publication date
CA2459586A1 (en) 2003-03-20
DK1425038T3 (da) 2006-03-27
WO2003022306A2 (en) 2003-03-20
CA2460025A1 (en) 2003-03-20
DE60207278T3 (de) 2011-05-05
EP1425038B1 (de) 2005-11-09
US20110189225A1 (en) 2011-08-04
DK1425037T3 (da) 2006-03-27
ATE308991T1 (de) 2005-11-15
EP1425037A2 (de) 2004-06-09
EP1425038A1 (de) 2004-06-09
EP1425038B2 (de) 2010-09-01
US8318148B2 (en) 2012-11-27
AU2002321644B2 (en) 2008-03-13
US20110200638A1 (en) 2011-08-18
US20040253710A1 (en) 2004-12-16
DE60207278T2 (de) 2006-08-10
ES2256515T5 (es) 2011-02-25
US7943122B2 (en) 2011-05-17
EP1425037B1 (de) 2005-11-09
DE60207277T2 (de) 2006-08-03
DE60207277D1 (de) 2005-12-15
US20050054075A1 (en) 2005-03-10
WO2003022307A1 (en) 2003-03-20
ES2256514T3 (es) 2006-07-16
DK1425038T4 (da) 2010-12-13
GB0121998D0 (en) 2001-10-31
ES2256515T3 (es) 2006-07-16
US7951361B2 (en) 2011-05-31
DE60207278D1 (de) 2005-12-15
WO2003022306A3 (en) 2003-06-26
AU2002321652B2 (en) 2008-04-10

Similar Documents

Publication Publication Date Title
ATE308992T1 (de) Attenuierte bakterien verwendbar als impstoffe
MA29459B1 (fr) Vaccins
ATE451119T1 (de) Untereinheit-impfstoff gegen das respiratorische synzytialvirus
DK1741442T3 (da) Neisseria meningitidis-kombinationavacciner
ATE357249T1 (de) Auf bläschen basierendes impfstoff gegen chlamydia
HUP0203056A1 (hu) Vakcinakészítmény
NO980883L (no) Forbindelser og fremgangsmÕter for immunterapi og diagnose av tuberkulose
WO1998053075A3 (en) Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
WO2002053180A3 (en) Immunizing compositions and methods of use
DE60037900D1 (de) Chlamydia antigene und entsprechende dna-fragmente und ihre verwendungen
WO2002024739A3 (en) Spas-1 cancer antigen
NO20004781D0 (no) Svekkede bakterier anvendelige i vaksiner
ATE413888T1 (de) Salmonella vakzine
DK1154791T3 (da) Neisseria-vaccinesammensætninger og fremgangsmåder
EP1908839A3 (de) Virulenzgene, Proteine und ihre Anwendung
AU2001284354A1 (en) Immunological adjuvant compounds, compositions, and methods of use thereof
BR0209145A (pt) Vacina contra varìola
DE602004023196D1 (de) Vakzine zusammensetzung zur impfung von hunden gegen infektiöse atemwegserkrankung bei hunden (cird)
DK1074266T3 (da) Levende svækkede bakterier til anvendelse i vaccine
ATE495757T1 (de) Attenuierte bakterielle lebendvakzine
ATE324450T1 (de) Polypeptid, das neutralisierende antikörper gegen hiv induziert
WO2004083390A3 (en) Virulent systemic feline calicivirus
ATE424844T1 (de) Kombinationsvakzine für geflügel
RU2003122317A (ru) Средство, повышающее иммуногенные свойства столбнячного анатоксина
DE60238554D1 (de) Vakzine gegen infektionskrankheiten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1425038

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 1425038

Country of ref document: EP